Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended				6 Months Ended		12 Months Ended
	Jul. 31, 2020	Apr. 30, 2020	Jul. 31, 2019	Apr. 30, 2019	Jul. 31, 2020	Jul. 31, 2019	Jan. 31, 2020	Jul. 31, 2020	Jan. 31, 2020	Jul. 31, 2019
Cash flows from operating activities:
Net income	$ 10,587	$ (3,975)	$ 12,271	$ 3,761	$ 6,612	$ 16,032
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization					47,738	44,766
Stock-based compensation, excluding cash-settled awards					31,567	37,605
Change in fair value of future tranche right	13,610		0		13,610	0
Amortization of discount on convertible notes					6,400	6,163
Non-cash gains on derivative financial instruments, net					(550)	(728)
Other, net					250	3,305
Changes in operating assets and liabilities, net of effects of business combinations:
Accounts receivable					70,174	23,439
Contract assets					4,292	7,884
Inventories					(1,572)	(4,436)
Prepaid expenses and other assets					(1,982)	8,169
Accounts payable and accrued expenses					11,891	(8,291)
Contract liabilities					(57,753)	(24,460)
Other, net					6,054	(11,169)
Net cash provided by operating activities					136,731	98,279
Cash flows from investing activities:
Cash paid for business combinations, including adjustments, net of cash acquired					0	(49,258)
Purchases of property and equipment					(16,040)	(17,718)
Purchases of investments					(92,865)	(20,101)
Maturities and sales of investments					30,791	23,836
Cash paid for capitalized software development costs					(6,224)	(6,581)
Change in restricted bank time deposits, and other investing activities, net					15,850	3,807
Net cash used in investing activities					(68,488)	(66,015)
Cash flows from financing activities:
Proceeds from issuance of preferred stock and future tranche right, net of issuance costs					197,254	0
Proceeds from borrowings					155,000	0
Repayments of borrowings and other financing obligations					(3,794)	(3,194)
Payments to repurchase convertible notes					(13,032)	0
Payments of debt-related costs					(2,207)	(212)
Purchases of treasury stock					(36,836)	(474)
Distributions paid to noncontrolling interest					(649)	(655)
Payments of deferred purchase price and contingent consideration for business combinations (financing portion) and other financing activities					(11,834)	(22,601)
Net cash provided by (used in) financing activities					283,902	(27,136)
Foreign currency effects on cash, cash equivalents, restricted cash, and restricted cash equivalents					(796)	(1,890)
Net increase in cash, cash equivalents, restricted cash, and restricted cash equivalents					351,349	3,238
Cash, cash equivalents, restricted cash, and restricted cash equivalents, beginning of period		411,657		412,699	411,657	412,699	$ 412,699
Cash, cash equivalents, restricted cash, and restricted cash equivalents, end of period	763,006		415,937		763,006	415,937	411,657
Reconciliation of cash, cash equivalents, restricted cash, and restricted cash equivalents at end of period to the condensed consolidated balance sheets:
Cash and cash equivalents								$ 731,101	$ 379,146	$ 388,546
Restricted cash and cash equivalents included in restricted cash and cash equivalents, and restricted bank time deposits								22,890		23,702
Restricted cash and cash equivalents included in other assets								9,015		3,689
Total cash, cash equivalents, restricted cash, and restricted cash equivalents	$ 763,006	$ 411,657	$ 415,937	$ 412,699	$ 763,006	$ 415,937	$ 412,699	$ 763,006	$ 411,657	$ 415,937